Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Adlinda Alip's publication output changed over time?
ScholarIQpublication output · 2018–2025
Output grew0% over the shown period — from 2 works in 2018 to 2 in 2025.
2
1
1
1
1
3
2
2018201920202022202320242025
What are the most-cited papers on Adlinda Alip?
ScholarIQmost cited works
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
Byoung Chul Cho, Shun Lu, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Jong-Seok Lee, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee‐Chen Chang, Hiroshige Yoshioka, James Chih‐Hsin Yang, Michael J. Thomas, Danny Nguyen, Sai‐Hong Ignatius Ou, Sanjay Mukhedkar, Kumar Prabhash, M. D’Arcangelo, Jorge Alatorre-Alexander, Juan Carlos Vázquez Limón, Sara Alves, Daniil Stroyakovskiy, Marina Peregudova, Mehmet Alı Nahıt Şendur, Ozan Yazıcı, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Antonio Passaro, Sang‐We Kim, Shirish M. Gadgeel, John Xie, Tao Sun, Melissa Martínez, Mariah Ennis, E. Fennema, Mahesh Daksh, Dawn Millington, Isabelle Leconte, Ryota Iwasawa, Patricia Lorenzini, Mahadi Baig, Sujay Shah, Joshua Bauml, S. Martin Shreeve, Seema Sethi, R.E. Knoblauch, Hidetoshi Hayashi
New England Journal of Medicine. 2024412 CitationsOPEN ACCESS
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Y.-L. Wu, D. Planchard, Shun Lü, Hao Sun, N. Yamamoto, Dongwook Kim, Daniel Shao-Weng Tan, James Chih‐Hsin Yang, M. Azrif, Tetsuya Mitsudomi, K Park, Ross A. Soo, John Wen‐Cheng Chang, Adlinda Alip, Solange Peters, J.-Y. Douillard
Annals of Oncology. 2018302 CitationsOPEN ACCESS
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
K. Park, Johan Vansteenkiste, Ki Hyeong Lee, G. Pentheroudakis, Caicun Zhou, Kumar Prabhash, Takashi Seto, P.J. Voon, Daniel S.W. Tan, James Chih‐Hsin Yang, J. Wang, K. Govind Babu, Yuko Nakayama, Adlinda Alip, Kevin Lee Min Chua, Jason Chia‐Hsien Cheng, Suresh Senan, Yong Chan Ahn, T.-Y. Kim, Hee Kyung Ahn, Solange Peters, Takayuki Yoshino, Jean-Yves Douillard
Annals of Oncology. 2020114 CitationsOPEN ACCESS
Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC
James Chih‐Hsin Yang, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Yu Jung Kim, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Antonio Passaro, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee-Chen Chang, Hiroshige Yoshioka, Michael Thomas, Danny T. Nguyen, Sai‐Hong Ignatius Ou, Sanjay Mukhedkar, Kumar Prabhash, M. D’Arcangelo, Jorge Alatorre-Alexander, Juan Carlos Vázquez Limón, Sara Alves, Daniil Stroyakovskiy, Marina Peregudova, Mehmet Alı Nahıt Şendur, Ozan Yazıcı, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Sang‐We Kim, Shirish M. Gadgeel, Scott Owen, John Xie, Tao Sun, Jaydeep Mehta, Raja Venkatasubramanian, Mariah Ennis, E. Fennema, Mahesh Daksh, Amy Roshak, Julie Man, Roland E. Knoblauch, Joshua Bauml, Mahadi Baig, Sujay Shah, Seema Sethi, Byoung Chul Cho
New England Journal of Medicine. 2025107 Citations
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Enriqueta Felip, Byoung Chul Cho, V. Gutiérrez, Adlinda Alip, Benjamin Besse, Shaolin Lü, Alexander I. Spira, N. Girard, Raffaele Califano, S.M. Gadgeel, James Chih‐Hsin Yang, Sadamu YAMAMOTO, K. Azuma, Yu Jung Kim, K.-H. Lee, Pongwut Danchaivijitr, C.G. Ferreira, Yun Cheng, Mehmet Alı Nahıt Şendur, G.-C. Chang, C.-C. Wang, K. Prabhash, Y. Shinno, Daniil Stroyakovskiy, L. Paz-Ares, Jerónimo Rafael Rodríguez‐Cid, Claire Martin, M.R. García Campelo, H. Hayashi, Danny Nguyen, P. Tomasini, Maya Gottfried, Christophe Dooms, Antonio Passaro, Martin Schüler, A.C.Z. Gelatti, Scott Owen, K. Perdrizet, S.-H.I. Ou, J.C. Curtin, J. Zhang, Michael Gormley, Tingting Sun, Amey C Panchal, Marguerite Ennis, E. Fennema, Mahesh Daksh, Seema Sethi, J.M. Bauml, S.-H. Lee
Annals of Oncology. 202485 CitationsOPEN ACCESS
Related on ScholarIQ
University of Malaya
Institution
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
Paper
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Paper
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
Paper
Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC
Paper
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Paper